AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19381692
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy sleep intervention
Trial: 1586710
Drug: Cytoxan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoxan (120 mg/kg) with total body irradiation (CYTBI)
Trial: 1586710
Drug: busulfan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: busulfan (16 mg/kg) (BUSCY)
Trial: 31813662
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based chemotherapy (epirubicin)
Trial: 30572281
Drug: Platelet-poor plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-poor plasma (PPP) injection
Trial: 15532360
Drug: Day 2-Control
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 2-Control group (one retention test administered 24 hr after practice)
Trial: 15532360
Drug: Day 1-Day
RxNorm normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1-Day 1 group (two retention tests administered 10 min and 20 min after practice)
Trial: 10936742
Drug: Dienogest 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 0.5 mg + Oestradiol valerate 2.0 mg
Trial: 10936742
Drug: Dienogest 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2.0 mg + Oestradiol valerate 2.0 mg
Trial: 10936742
Drug: Dienogest 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 3.0 mg + Oestradiol valerate 2.0 mg
Trial: 10936742
Drug: Dienogest 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 4.0 mg + Oestradiol valerate 2.0 mg
Trial: 15725969
Drug: Methylphenidate 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.6 mg/kg
Trial: 31326433
Drug: Glepaglutide 10
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glepaglutide 10 mg
Trial: 31504303
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet of sofosbuvir and daclatasvir with or without ribavirin
Trial: 25033291
Drug: Mefloquine-artesunate (3×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine-artesunate (3× (100 mg artesunate + 250 mg mefloquine)) + Praziquantel (40 mg/kg)
Trial: 18490845
Drug: Kampo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kampo (two capsules containing powdered ginseng 250 mg, powdered oriental bezoar 50 mg, and powdered glycyrrhiza 50 mg)
Trial: 15727498
Drug: Naloxone 0.1
RxNorm normalized name: naloxone 0.18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.1 mg/70 kg
Trial: 15727498
Drug: Drug reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug reinforcement opportunity (fentanyl 1.5 mg/70 kg iv)
Trial: 10599652
Drug: 8 fractions
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 fractions of 0 Gy (sham treatment)
Trial: 7854516
Drug: High-level vagus
RxNorm normalized name: Sus scrofa vagus nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level vagus nerve stimulation (presumed therapeutic dose)
Trial: 7854516
Drug: Low-level vagus
RxNorm normalized name: Sus scrofa vagus nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level vagus nerve stimulation (presumed subtherapeutic dose)
Trial: 7015799
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release quinidine 0.4 g twice a day
Trial: 7015799
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg three times a day
Trial: 22192386
Drug: Pedicled buccal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedicled buccal fat pad flap (PBFPF)
Trial: 22192386
Drug: Classic buccal
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic buccal sliding flap
Trial: 16295337
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of integrative and computerised learning
Trial: 9563887
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 450 mg/m2 i.v. for 5 days followed by 15 mg/kg i.v. weekly (arm 1)
Trial: 9563887
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) plus levamisole 50 mg p.o. every 8 h for 3 days every 2 weeks (arm 2)
Trial: 28002447
Drug: Granisetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1 mg/mL)
Trial: 16374685
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) supplementation at a dosage of 3.1 ± 0.6 mg/kg/day for 9 months
Trial: 16374685
Drug: Conventional antifailure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antifailure drugs
Trial: 12357147
Drug: 8-mg OROS
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg OROS formulation
Trial: 12357147
Drug: 8-mg IR
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg IR formulation
Trial: 12357147
Drug: OROS formulation
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS formulation
Trial: 2007362
Drug: Clofazimine 100
RxNorm normalized name: clofazimine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 100 mg daily (N = 25)
Trial: 7124726
Drug: 7.05% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.05% NaCl (osmotic activity equivalent to 15 ml of 23.5% NaCl)
Trial: 27898183
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 µg twice daily (EXE)
Trial: 17921706
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving surgery (BCS) plus radiation therapy (RT)
Trial: 15067339
Drug: Oral 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-fluorouracil (5-FU) for 1 year in patients receiving surgery and radiotherapy (SR)
Trial: 15067339
Drug: Oral 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-fluorouracil (5-FU) for 1 year in patients with pelvic lymph node metastases
Trial: 11340355
Drug: Dilazep dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep dihydrochloride (300 mg/day) in normotensive patients (group A)
Trial: 11340355
Drug: Dilazep dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep dihydrochloride (300 mg/day) in hypertensive patients (group C)
Trial: 7758055
Drug: Piperacillin/tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours
Trial: 2100659
Drug: Anode Iontophoresis
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anode Iontophoresis using Strontium Chloride Solution (9%)
Trial: 2100659
Drug: Anode Iontophoresis
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anode Iontophoresis using Strontium Chloride gel (9%)
Trial: 2100659
Drug: Cathode Iontophoresis
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathode Iontophoresis using Sodium Fluoride gel (2%)
Trial: 31713940
Drug: 5α-reductase inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5α-reductase inhibitors
Trial: 31713940
Drug: 5α-reductase inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5α-reductase inhibitors (at least 3 years use)
Trial: 26025794
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib for 3 days followed by oral celecoxib for 4 days
Trial: 26025794
Drug: COX-2-specific inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2-specific inhibitors
Trial: 15124669
Drug: G-CSF priming
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF priming
Trial: 22491395
Drug: Modified Early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Trial: 17207028
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg/day for 3 days)
Trial: 17207028
Drug: Cefcapene pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefcapene pivoxil hydrochloride (300 mg/day for 3 days)
Trial: 3311904
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (control group)
Trial: 2636644
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.4 g/kg body wt/day of protein and 0.1 g/kg body wt/day of essential amino acids)
Trial: 342628
Drug: Monovalent A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent A/New Jersey/76 influenza virus vaccines (two-dose regimens)
Trial: 342628
Drug: Split-virus and
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-virus and whole-virus vaccines
Trial: 342628
Drug: Two whole-virus
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two whole-virus vaccines
Trial: 21522097
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral clonidine)
Trial: 20137491
Drug: Octride alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octride alone (octride treatment group)
Trial: 16885180
Drug: Thrice-daily tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Thrice-daily tobramycin (divided into three equal doses every 8 hours)
Trial: 14713803
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tolterodine ER once daily for 12 weeks
Trial: 8538704
Drug: Acellular DTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular DTP vaccines
Trial: 9041666
Drug: Acellular vaccine
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccine recipients
Trial: 9272346
Drug: Acellular vaccines
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccines
Trial: 3253217
Drug: Furosemide 20
RxNorm normalized name: furosemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 20 mg administered at 21h00
Trial: 3253217
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 09h00
Trial: 3253217
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 21h00
Trial: 3253217
Drug: Furosemide 20
RxNorm normalized name: furosemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 20 mg administered at 09h00
Trial: 31690004
Drug: BBPAS (Brain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBPAS (Brain Breaks Physical Activity Solutions)
Trial: 26840038
Drug: Impaired fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired fasting glucose (100-125 mg/dL)
Trial: 9060793
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg once per day) plus placebo; n = 14
Trial: 9060793
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg two times per day) plus placebo; n = 18
Trial: 9060793
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg once per day) plus Nisoldipine (10 mg two times per day); n = 14
Trial: 8342506
Drug: Type IA
RxNorm normalized name: MAGNESIUM ALUMINUM SILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type IA antiarrhythmic therapy
Trial: 3485054
Drug: PAMBA (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAMBA (1.0 g)
Trial: 23402088
Drug: Topical Glyceril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Glyceril trinitrate ointment (0.2%)
Trial: 23402088
Drug: Topical Diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Diltiazem gel (2%)
Trial: 18697207
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a at 270 microg/week plus ribavirin at 1200 mg/day
Trial: 18697207
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a at 180 microg/week plus ribavirin at 1600 mg/day
Trial: 10547245
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg OspA vaccine
Trial: 9081395
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone 4 mg twice daily as maintenance
Trial: 26912506
Drug: Remifentanil (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (i.v. infusion 1-5 µg/kg/h)
Trial: 26912506
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 0.3-0.4 µg/kg followed by i.v. infusion 0.2-1 µg/kg/h)
Trial: 22465256
Drug: Weekly, group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly, group-based weight management intervention with individualized calorie intake goal, second counseling session, and weekly group meetings until birth.
Trial: 22465256
Drug: Weekly, group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly, group-based weight management intervention.
Trial: 8698011
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment comparison
Trial: 6370748
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone valerate ointment
Trial: 7760093
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg thiopental
Trial: 7129299
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg methohexital
Trial: 28705573
Drug: Axitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (oral administration for up to 12 weeks)
Trial: 14716340
Drug: Immunotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (group B, n=7)
Trial: 14716340
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (group A, n=6)
Trial: 14716340
Drug: Immunotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy in patients relapsing directly into CRel (n=4)
Trial: 20456815
Drug: Roasted unsalted
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roasted unsalted peanuts (56 g daily for 4 weeks)
Trial: 20456815
Drug: Roasted salted
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roasted salted peanuts (56 g daily for 4 weeks)
Trial: 14698710
Drug: Magnet-activated stimulation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnet-activated stimulation during VNS therapy
Trial: 8791276
Drug: Interferon-alpha and
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha and high dose interleukin-2
Trial: 1365669
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg co-dergocrine mesylate (CDM)
Trial: 1365669
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg co-dergocrine mesylate (CDM)
Trial: 2857949
Drug: Paracentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracentesis plus intravenous albumin infusion
Trial: 10509569
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy and ZDV/ddl combination
Trial: 1818427
Drug: Nizoral cream
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizoral cream
Trial: 31159765
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg/day (3 weeks followed by 1 week rest)
Trial: 29176762
Drug: Prenatal lifestyle
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal lifestyle intervention (twice weekly group-exercises and dietary counseling)
Trial: 30964416
Drug: Interaction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interaction of H. halys and Fusarium treatments
Trial: 22894890
Drug: Chamomile extract
RxNorm normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile extract (220 mg capsules standardized to 1.2% apigenin)
Trial: 18760137
Drug: Antidiabetes regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetes regimens targeting insulin sensitivity
Trial: 10634023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BTA treatment)
Trial: 8550117
Drug: Diazepam and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam and Alcohol (combination)
Trial: 8550117
Drug: Alcohol and
RxNorm normalized name: Polyvinyl alcohol and povidone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol and Propranolol (combination)
Trial: 8550117
Drug: Diazepam and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam and Propranolol (combination)
Trial: 23281420
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (control group)
Trial: 22906730
Drug: Grape extract
RxNorm normalized name: grape extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape extract (GE) tablets
Trial: 19151458
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg intravenous midazolam
Trial: 19151458
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 5mg diazepam + 25 mg promethazine
Trial: 11388472
Drug: MBP (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP (40 mg per day)
Trial: 9554821
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate suspension
Trial: 1048183
Drug: Trimethoprim-sulfamethoxazole (TMP/SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP/SMX) 10 mg TMP and 50 mg SMX/KG/day orally in two divided doses
Trial: 1048183
Drug: Ampicillin 100
RxNorm normalized name: ampicillin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 100 mg/kg/day orally in four divided doses
Trial: 21497049
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral cataract surgery (2 sessions, 4 to 6 weeks apart)
Trial: 15257743
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + subgingival administration of 10% doxycycline hyclate gel
Trial: 15257743
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + subgingival placebo gel
Trial: 7871035
Drug: CP-88,059-1 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-88,059-1 (2 mg to 60 mg)
Trial: 21858267
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug (combination of primrose, gentian root, vervain, elder flowers, and sorrel: Sinupret)
Trial: 19117801
Drug: Physician directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician directed product administration
Trial: 9145738
Drug: Intravenous ampicillin/sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin/sulbactam followed by oral amoxicillin/clavulanate for 14-28 days
Trial: 19650932
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg